EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency

Alice M Turner, Joachim H Ficker, Andrea Vianello, Christian F Clarenbach, Sabina Janciauskiene, Joanna Chorostowska-Wynimko, Jan Stolk, Noel Gerard McElvaney

Therapeutic Advances in Respiratory Disease · 2025-01 · 19

DOI: 10.1177/17534666251318841 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 20.02.2025. Verfasst von Alice M Turner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Applied Health Research, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, alpha 1-Antitrypsin, Pulmonary Emphysema, Lung Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Behring. Medical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alpha 1 antitrypsin deficiency (AATD) is a genetic disorder that alters the functionality and/or serum levels of alpha 1 antitrypsin (AAT). Dysfunctional forms of AAT, or low levels of serum AAT, predispose affected individuals to pulmonary complications. When AATD-associated lung disease develops, the most common pulmonary pathology is emphysema. The development of emphysema and decline in lung function varies by AATD genotype and is accelerated by risk factors, such as smoking. To improve the understanding and treatment of AATD, emerging knowledge and unresolved questions need to be discussed. Here we focus on developments in the areas of disease pathogenesis, biomarkers, and clinical endpoints for trials in AATD, as well as barriers to treatment. The clinical impact of AATD on lung function is highly variable and highlights the complexity of AATD pathogenesis, in which multiple underlying processes are involved. Reduced levels of functional AAT disrupt the protease-antiprotease homeostasis, leading to a loss of neutrophil elastase inhibition and the breakdown of elastin within the lung interstitium. Inflammatory processes also play a critical role in the development of AATD-associated lung disease, which is not yet fully understood. Biomarkers associated with the disease and its complications may have an important role in helping to address AATD underdiagnosis and evaluating response to treatment. To improve access to treatment, the problem of underdiagnosis needs to be addressed and the provision of therapeutic options needs to become uniform. Patients should also be empowered to play a key role in the self-management of the disease. Advancing our understanding of the disease will ultimately improve the life expectancy and quality of life for patients affected by AATD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin Deficiencyalpha 1-AntitrypsinPulmonary EmphysemaLung DiseasesHumansBiomarkersRisk FactorsLungGenotype

Stichwörter der Autor:innen

AATAATDCOPDFEV1SERPINA1 genealpha 1 antitrypsinalpha 1 antitrypsin deficiencybarriers to treatmentbiomarkersclinical endpointsdisease managementdisease pathogenesisemphysemagenetic variantsrare disease

Substanzen

alpha 1-AntitrypsinBiomarkers

Autor:innen und Institutionen

  • Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuernberg and Paracelsus Medical University, Nuernberg, Germany.
  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Department of Pulmonology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Department of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL), Hannover, Germany.
  • Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.

Förderung

  • CSL Behring. Medical

Zitieren

APA

Turner, A. M., Ficker, J. H., Vianello, A., Clarenbach, C. F., Janciauskiene, S., Chorostowska-Wynimko, J., Stolk, J., & McElvaney, N. G. (2025). Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251318841

Vancouver

Turner AM, Ficker JH, Vianello A, Clarenbach CF, Janciauskiene S, Chorostowska-Wynimko J, et al. Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251318841

BibTeX
@article{Turner2025,
  author = {Turner, Alice M and Ficker, Joachim H and Vianello, Andrea and Clarenbach, Christian F and Janciauskiene, Sabina and Chorostowska-Wynimko, Joanna and Stolk, Jan and McElvaney, Noel Gerard},
  title = {Advancing the understanding and treatment of lung pathologies associated with alpha 1 antitrypsin deficiency},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  volume = {19},
  doi = {10.1177/17534666251318841}
}
Kostenlos starten →